FICC Focus Delos’ Lefkovits on Private Credit, Default Trend: Credit Crunch
Feb 28, 2025
Ari Lefkovits, managing partner at Delos Capital, shares insights on hybrid capital solutions aimed at helping SMEs deal with high borrowing costs. The discussion uncovers trends in the private credit market, revealing the shift towards co-op agreements among lenders and the evolving default process. Lefkovits also highlights how hybrid capital can provide financial advantages amidst inflation and tariffs. This conversation offers a fascinating look at the current financial landscape and its implications for small businesses.
AI Snips
Chapters
Transcript
Episode notes
Darzalex Dominance in Myeloma
- Darzalex is the leading therapy for multiple myeloma, especially in frontline treatment.
- More growth potential exists in transplant-ineligible patients and maintenance therapy.
CAR T-Cell Therapy Uptake
- Carvykti and Abecma, CAR T-cell therapies, show promising uptake in relapsed/refractory myeloma.
- Cost remains a barrier to wider adoption, especially in Europe, where approvals are limited.
Moderna and Vaccine Uncertainty
- Moderna's bird flu vaccine contract reevaluation signals uncertainty about future mRNA vaccine prospects.
- Cancelled meetings and potential delays raise concerns about the broader vaccine landscape.